Precision BioSciences Q2 Loss Widens to $1.26/Share on Warrant Charge; Cash Runway Through 2028
DTIL sits 94% above its 52-week low of $3.53.
Summary
Precision BioSciences reported a Q2 net loss of $1.26 per share, wider than expected due to a non-cash warrant liability charge. Revenue was zero, unchanged from the prior period. The company ended the quarter with $112.4 million in cash, which it expects to fund operations through 2028. Clinical updates for the PBGENE-HBV and PBGENE-DMD programs are targeted by year-end 2026, with initial safety data from the FUNCTION-DMD trial also expected by then. The loss was driven by a change in fair value of warrant liabilities, while R&D and G&A expenses declined. This follows positive clinical data reported in May and a leadership overhaul announced in July.
At the time of this announcement, DTIL was trading at $6.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $192.7M. The 52-week trading range was $3.53 to $9.62. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.